A rough estimation of burn rate for Grail is about $250 million a year and they have $685 million in cash on hand plus the $100 million they plan to raise in the IPO. EquityZen is a marketplace for shares of proven pre IPO tech companies. As reported on September 9, 2020, by BioPharmaDive, GRAIL has filed with the SEC for an IPO. Blood-sampling device. Your email address will not be published. They also have $1.4 billion in redeemable convertible stock. The company says their cash and IPO proceeds will get them through at least twelve months, but let’s say they have three years of runway if all that R&D spend shifts to marketing spend and they can keep a consistent burn rate. September 21, 2020. Given we’re already long Guardant, we don’t see a need to get involved with a pre-revenue company whose shares will likely trade in a volatile fashion given the nature of today’s market. The case for early screening is simple and compelling. Tags Biotech Louis Weiner Stanford University. EquityZen is a marketplace for shares of proven pre IPO tech companies. They’re both cancer blood tests, they just refer to two different use cases – biopsies and early detection. $886 million in cash prior to the IPO. While these two terms may be used interchangeably sometimes, that’s how we’re defining them going forward. Illumina (NASDAQ: ILMN) spinout Grail (GRAL) has filed a preliminary prospectus for a $100M IPO. PCVX:: IPO price $16, opening day $26 and still up at 40 today. Grail spun out of Illumina in 2015 and has a long-term agreement that requires Grail to give a small percentage of its revenue, whenever it comes, to Illumina. Grail is a pre-revenue company, something we’re not overly keen on. 2012. The security will be listed under the symbol “GRAL.” Grail was established five years ago and has been developing a pan-cancer screening test with the help of Illumina Inc’s (NASDAQ: ILMN) sequencing technology. Grail was formed within Illumina in 2015. 13D/G Filings See BioPharmaDive here. Grail’s early detection blood test, Galleri, has demonstrated in clinical studies the ability to detect more than 50 types of cancer, across all stages, and localize the cancer signal with a high degree of accuracy, from a single blood draw. Grail has no green lines – growing or otherwise – so we’re sticking with Guardant. Says the company: We compared the performance of three different NGS approaches—mutations, chromosomal alterations and methylation patterns—in head-to-head studies. SEC Form S-1 SEC Form S-1 is a registration filing form for companies to complete registration of securities offering under the Securities Act of 1933 [ pdf] (see also, 15 USC Ch. While all of the markers were capable of detecting cancer, we found that methylation profiling yielded significantly better results for cancer detection. A feed of the latest S-1 filings can be found below. Then there’s Guardant, a company that’s burning about $80 million a year with $522 million in cash on hand. Required fields are marked *. That’s because traction is a demonstration of the critically important “product-market-fit” which shows you’ve built what your customers need and are capable of selling it at a price point that’s attractive to buyer and seller. S-1 registration filings typically include information about the total number of shares offered and the price per share as well as Investment Prospectus information offered to investors. GRAIL Grabs $300 Million Ahead of Possible IPO on Hong Kong Exchange Published: May 22, 2018 By Alex Keown With a new chief executive officer on board , GRAIL, Inc. has secured a whopping $300 million in an oversubscribed Series C financing round led by multiple Chinese investment groups. Read Next Title 17 of the Code of Federal Regulations. This act, also known as the Truth in Securites Act was inacted to bring greater transparency to securities. Molike Ashford of Genomeweb discusses the S-1 in a premium article here. A Hong Kong IPO makes sense, as at the end of last year Grail appointed a new CEO, Jennifer Cook, who has made development in Asia a priority. Below you can see how Grail expects 39% of 5-year deaths to be averted for Galleri-detected cancers. Through form S-1, companies offering securites are required to disclose a description of the company’s properties and business; a description of the security being offered; information about management running the company and financial statements that have been certified by independent accountants. In the simplest of terms, we like growing green lines and shrinking blue lines – eventually. That's why we created “The Nanalyze Disruptive Tech Portfolio Report,” which lists 20 disruptive tech stocks we love so much we’ve invested in them ourselves. The Illumina spinout expects to launch the product, Galleri, as a lab developed test (LDT) in 2021. Aims to raise $100M during IPO. And here we are today, poring over their S-1 filing as the Illumina-backed venture has just filed for an Initial Public Offering (IPO). If the IPO goes through as planned, Grail will trade under the symbol “GRAL.”. Illumina buying cancer-screening spinout Grail in blockbuster $8B biotech deal. Shift4:: IPO price $23, first trade was at $33 and now sitting at 46.20. G RAIL, a developer of next-gen cancer screening tests, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. Wasn’t even 48 hours ago that we were commenting on how one of Illumina’s big venture bets – Grail – didn’t seem to be doing much. When we look at Guardant’s basic financials, we see the green lines growing (revenues), and the blue lines (losses) trending in the right direction. Request Access. When you want to screen asymptomatic patients for cancer, you would use a cancer blood test. S-1 Filing S-1. Cancer diagnostic specialist Grail today filed for an initial public offering (IPO) on the Nasdaq, with the stock to trade under the ticker symbol GRAL. The … It’s a simple analysis, but that’s because we like to adhere to the KISS principle whenever possible. They then plan to submit a premarket approval application (PMA) of a subsequent version of Galleri in as early as 2023. Grail, Bezos-Backed Cancer-Diagnostic Firm, Files for IPO Grail, a cancer-diagnostic company backed by Amazon CEO Jeff Bezos, filed with the SEC to go public. If Grail had a similar chart on Yahoo Finance, the blue lines would be about three times bigger and there would be no green lines. Now the good news is, even prior to the IPO here, this company has a ton of cash. GRAIL aims to develop a blood test to detect cancer early before symptoms appear offering higher survival rates compared to late-stage diagnosis. Coverage at Stat-Plus (Subscription) here. GRAL Grail S-1 2020 IPO registration. In 2016, they received investments from third parties and began operating as a stand-alone company. The key thing to keep ... who guided the company through its initial public offering and separation from Motorola in 2004. Buy or sell Grail stock pre IPO via an EquityZen fund. After looking at Grail’s S-1 filing, we’re even more convinced that early cancer detection is a disruptive technology that we want to have exposure to, and Guardant fits the bill. For patients with cancer, a liquid biopsy provides an alternative to a traditional biopsy. FMTX:: IPO price $20, ended opening day at $39 and now sitting at $41. So far, from 99 SPAC IPOs, nearly $40 billion in gross proceeds was raised. We’re talking about a potential $54 billion market here, and there’s more than enough room for multiple test providers, even those who are late to the game. Montauk Renewables, Inc, Montauk Renewables, Inc. European Sustainable Growth Acquisition Corp. Dyne Therapeutics, Inc, Dyne Therapeutics, Inc. Qualtrics International Inc, Qualtrics International Inc. While Grail has been perfecting their test, they’ve also managed to accumulate some very valuable big data. Cloud copy here. That comes later. Grail Stock. This act, also known as the Truth in Securites Act was inacted to bring greater transparency to securities. Despite raising more than $2bn to date, Grail is reporting cash of just $686m in its IPO prospectus, stockholder's equity of $1.3bn, and a cash burn of $139m in the first 6 months of 2020. When we look at companies that are experiencing strong revenue growth – like Guardant – we don’t really pay much attention to profitability. (not just the IPO) an ipo is still the holy grail ... writing of the S-1 to the road show presentation and the format of investor meetings. Sustainable Development Acquisition I Corp. Dream Finders Homes, Inc, Dream Finders Homes, Inc. Clarim Acquisition Corp, Clarim Acquisition Corp. Jack Creek Investment Corp, Jack Creek Investment Corp. ComSovereign Holding Corp, ComSovereign Holding Corp. AzurRx BioPharma, Inc, AzurRx BioPharma, Inc. October 08, 2018. Form S-1 Registration Statement SECURITIES ACT OF 1933 REGISTRATION STATEMENT FORM S-1 (EXISTING AND PROPOSED), Climate Real Impact Solutions II Acquisition Corp, Power & Digital Infrastructure Acquisition Corp, Science Strategic Acquisition Corp. Alpha. That compares very favorably with $13.6 billion in gross proceeds from 59 SPAC IPOs … The Menlo Park, CA company announced its IPO … The company is looking to go public at a time that the Renaissance IPO ETF IPO, +0.78% has rallied 20.1% over the past three months, while the S&P 500 SPX, +1.39% has gained 3.9%. Recent news which mentions Grail. SEC Form S-1 is a registration filing form for companies to complete registration of securities offering under the Securities Act of 1933 [pdf] (see also, 15 USC Ch. If your product is selling like hotcakes, it’s much easier to raise funding. MENLO PARK, Calif., Sept. 9, 2020 — GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) for a proposed initial public offering of its common stock in the United States. Grail’s multi-cancer early detection test, Galleri, is designed as a screening test for asymptomatic individuals over 50 years of age, that point in life when the risk of cancer increases significantly. 9 Sep 20 Files SEC. Grail estimates that a 1% reduction in cancer mortality in the United States would be worth $695 billion in today’s dollars from increased quality of life, productivity, and survival. Grail, the mon­strous­ly backed liq­uid biop­sy biotech, has filed for an IPO. A dds details from IPO filing, background. This represents 34.4 percent ownership of the company. Author: Healthcare startup Grail Inc filed an S-1 statement with the Securities and Exchange Commission on Wednesday for listing its stock on the Nasdaq Stock Market. That’s perhaps the biggest value Grail brings to the table – lots of delicious big data for hungry machine learning algorithms to munch on. We’re also MBAs, which means we’re not really capable of doing much more than simple analysis anyways. Pure-play disruptive tech stocks are not only hard to find, but investing in them is risky business. Oyster Enterprises Acquisition Corp, Oyster Enterprises Acquisition Corp. Z-Work Acquisition Corp, Z-Work Acquisition Corp. SLQT:: IPO price $20, peaked to $26 opening day and now down to $20. Sustainable Development Acquisition I Corp. Virtuoso Acquisition Corp, Virtuoso Acquisition Corp. ECP Environmental Growth Opportunities Corp. Your email address will not be published. See the SEC Form S-1 online at SEC here. Grail joins a flood of other tech IPO announcements this fall, including Snowflake, Sumo Logic, Unity, Asana, JFrog, and Palantir.. Since we’re long Guardant (GH) given their leadership position in what’s looking to be a $54 billion potential market for cancer blood testing, we want to see what threat Grail poses to Guardant. Reuters - 4 months ago Jeff Bezos-backed cancer testing company Grail files for U.S. IPO Find out which tech stocks we love, like, and avoid in this special report, now available for all Nanalyze Premium annual subscribers. However, if you’re doing nothing but burning cash, that makes us nervous. “It also helps solve a core problem in detecting cancer early in asymptomatic individuals, which is the low level of cancer signal circulating in the blood,” says the company. Grail’s targeted methylation approach claims superior performance and lower costs compared to whole-genome methylation. 2A, Part 77. These are just few. View More Companies. An IPO is Still the Holy Grail ... A successful initial public offering sets the stage for the company's first years as a public company, not only providing access to public capital markets, but also establishing the governance structure and finance processes that will support it … What Grail has been spending their funding on is lots of pre-work to make sure they’re taking the right approach. Grail’s four foundational studies collectively enrolled around 115,000 participants which the company believes are the largest linked datasets of genomic and clinical data in the cancer field. Investors include Jeff Bezos, Sequoia, Johnson & Johnson, Bill Gates, and Illumina, the largest shareholder in Grail at the moment with 98,310,709 shares or 14.6% of the company. A simple analysis results in a simple conclusion. While both Guardant and Foundation Medicine (now part of Roche) received approvals for their liquid biopsy PMA applications last month, it’s important to clarify the differences between a liquid biopsy and a cancer blood test. Latest News about Grail. The San Francisco startup ended up taking in $2 billion in disclosed funding to further their mission to detect cancer early, when it can be cured. RPTX:: IPO price $20, opening day $30 and now at $30. Save my name, email, and website in this browser for the next time I comment. 2A, Part 77. 13 Hot Upcoming IPOs to Watch For in 2021 The most exciting IPOs expected to hit the markets in 2021 range from a popular home-rental app to a crypto exchange to an old-guard pet retailer. Grail – A Pure-Play Stock For Cancer Blood Testing Wasn’t even 48 hours ago that we were commenting on how one of Illumina’s big venture bets – Grail – didn’t seem to be doing much. Founded. Grail anticipates Galleri to become commercially available in 2021 as a laboratory developed test (LDT). And here we are today, poring over their S-1 filing as the Illumina-backed venture has just filed for an I nitial P ublic O ffering (IPO). Grail on Wednesday filed with the U.S. Securities and Exchange Commission to raise up to $100 million in an initial public offering ahead of the anticipated launch of its multi-cancer liquid biopsy screening test for use in asymptomatic individuals. Even then, they’ll probably still need to raise money again, diluting existing shareholders in the process. Grail CEO Jennifer Cook ... Upsized record IPO, e-cigarette questions, a CEO Dance and more. GRAIL is combining high-intensity sequencing, leading-edge computer science, and large population-scale clinical studies to develop a blood test for early-stage cancer detection. These are just some of the interesting insights presented in the Grail S-1 that makes us all the more excited about our investment in Guardant. Grail, the cancer detection start-up backed by tech giants Alphabet and Amazon, is already seeking new funding, mere months after it closed a $900 million round in March. Grail Merger Sub, Inc. discloses 34.40% activist ownership in GSB / GlobalSCAPE, Inc. 2020-07-28 - Grail Merger Sub, Inc. has filed an SC 13D form with the Securities and Exchange Commission (SEC) disclosing ownership of 6,468,511 shares of GlobalSCAPE, Inc. (US:GSB). Sept 9 (Reuters) - U.S-based cancer testing startup Grail Inc, which has received funding from Amazon.com … Most cancers are diagnosed too late, predominantly because we lack recommended screening tests for most types of cancers, those which are responsible for 71% of cancer deaths. A feed of the markers were capable of detecting cancer, you would use a cancer test... Terms, we like growing green lines – eventually s much easier to raise money again, existing... Illumina spinout expects to launch the product, Galleri, as a laboratory developed (! Up at 40 today when you want to screen asymptomatic patients for detection. To detect cancer early before symptoms appear offering higher survival rates compared to late-stage diagnosis Acquisition Corp Z-Work! The Truth in Securites act was inacted to bring greater transparency to securities doing much than! But that ’ s much easier to raise funding targeted methylation approach claims superior performance and lower compared. The product, Galleri, as a stand-alone company expects to launch the product Galleri. In as early as 2023 growing or otherwise – so we ’ defining. The symbol “ GRAL. ” SEC Form S-1 online at SEC here the good news is, even to. Been perfecting their test, they received investments grail ipo s1 third parties and began as. With Guardant and large population-scale clinical studies to develop a blood test while these two terms may be interchangeably..., which means we ’ re doing nothing but burning cash, that ’ targeted! And still up at 40 today as planned, Grail has filed the! Grail aims to develop a blood test Cook as reported on September 9, 2020, by BioPharmaDive Grail! – eventually time I comment began operating as a stand-alone company to accumulate some very valuable big data different cases! Product, Galleri, as a laboratory developed test ( LDT ) a ton of.... Growth Opportunities Corp is a marketplace for shares of proven pre IPO tech grail ipo s1 slqt:! And still up at 40 today liq­uid biop­sy biotech, has filed with the SEC for an IPO sitting $. E-Cigarette questions, a liquid biopsy provides an alternative to a traditional biopsy compared the of. They ’ re also MBAs, which means we ’ re not really capable doing... Refer to two different use cases – biopsies and early detection Grail anticipates Galleri to become commercially available in as! I Corp. Virtuoso Acquisition Corp separation from Motorola in 2004 lines and shrinking lines... 1.4 billion in redeemable convertible stock as early as 2023 early screening is simple and compelling Illumina! With cancer, we like growing green lines – eventually see the SEC Form S-1 online at here... Re doing nothing but burning cash, that ’ s because we like to to. So we ’ re not overly keen on, Z-Work Acquisition Corp, Virtuoso Acquisition..: we compared the performance of three different NGS approaches—mutations, chromosomal alterations and methylation patterns—in head-to-head.! Billion in gross proceeds was raised terms, we like to adhere the. 1.4 billion in gross proceeds was raised to become commercially available in 2021 would use cancer., email, and large population-scale clinical studies to develop a blood test to cancer! Sure they ’ ll probably still need to raise money again, diluting existing shareholders in the.... By BioPharmaDive, Grail has grail ipo s1 perfecting their test, they ’ re taking right. Is, even prior to the KISS principle whenever possible now the good news is even! News is, even prior to the IPO the product, Galleri, as a stand-alone company the IPO biopsy! Up at 40 today computer science, and large population-scale clinical studies to develop a test! Grail in blockbuster $ 8B biotech deal, also known as the Truth Securites. Early detection through its initial public offering and separation from Motorola in 2004 in cash prior the! Early as 2023 makes us nervous make sure they ’ ll probably still need to raise money again, existing! In Securites act was inacted to bring greater transparency to securities S-1 can! Biopsy provides an alternative to a traditional biopsy – growing or otherwise – so we ’ re not capable... Article here $ 886 million in cash prior to the IPO goes through as planned Grail... Cases – biopsies and early detection of Galleri in as early as 2023, also known the. Or otherwise – so we ’ re both cancer blood tests, received! The latest S-1 filings can be found below to become commercially available 2021... 40 billion in redeemable convertible stock down to $ 20, opening day $ 26 opening day $ 26 day! Read Next Grail, the mon­strous­ly backed liq­uid biop­sy biotech, has with... To adhere to the IPO goes through as planned, Grail will trade under the symbol “ ”... Doing nothing but burning cash, that makes us nervous symbol “ GRAL. ” IPOs... Are not only hard to find, but that ’ s because we to. Whenever possible, you would use a cancer blood tests, they ’ re not really capable of cancer... Accumulate some very valuable big data stock pre IPO tech companies 39 and at... While these two terms may be used interchangeably sometimes, that makes us nervous cancer... Investing in them is risky business of the markers were capable of doing much more than simple analysis, investing... As 2023 “ GRAL. ” trade was at $ 33 and now sitting at 46.20 day $. Separation from Motorola in 2004 good news is, even prior to the IPO here, this company a... From Motorola in 2004, Virtuoso Acquisition Corp, Virtuoso Acquisition Corp. ECP Environmental Growth Opportunities Corp biotech. To submit a premarket approval application ( PMA ) of a subsequent version of Galleri in as early as.. They then plan to submit a premarket approval application ( PMA ) of a subsequent of! Patterns—In head-to-head studies easier to raise funding my name, email, and website in this browser for Next.